NBIX
Neurocrine Biosciences Inc
NASDAQ: NBIX · HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC
$150.59
-2.07% today
Updated 2026-06-05
Market cap
$16.06B
P/E ratio
24.58
P/S ratio
5.18x
EPS (TTM)
$6.50
Dividend yield
—
52W range
$122 – $170
Volume
1.2M
WallStSmart proprietary scores
81
out of 100
Grade: A
Strong Buy
Investment rating
10.0
Growth
A+8.0
Quality
A8.0
Profitability
A7.0
Valuation
B+3/9
Piotroski F-Score
Weak
3.1
Altman Z-Score
Safe zone
—
Industry rank
—
View all highly rated stocks (75+) →202 stocks currently score above 75
Price targets
Analyst target
$190.99
+26.83%
12-Month target
$131.76
-12.50%
Intrinsic (DCF)
—
Margin of safety
—
4 Strong Buy20 Buy4 Hold0 Sell0 Strong Sell
Price chart
Stock snapshot
Strengths
+ Altman Z 3.08 — safe zone
+ Profit margin 21.50% — above average
+ Free cash flow $136.70M — positive
+ Revenue growth 42.20% QoQ
+ Debt/equity 0.12x — low leverage
Risks
- Piotroski 3/9 — weak financial health
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM | 2026 (E) |
|---|---|---|---|---|---|---|
| Revenue | $1.49B | $1.89B | $2.36B | $2.86B | $3.10B | $3.6B |
| Net income | $154.50M | $249.70M | $341.30M | $478.60M | $197.90M | — |
| EPS | — | — | — | — | $6.50 | $6.07 |
| Free cash flow | $322.90M | $361.60M | $557.20M | $748.70M | $136.70M | — |
| Profit margin | 10.38% | 13.23% | 14.49% | 16.73% | 21.50% | — |
Recent insider activity
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2026-06-02 | KESWANI, SANJAY CHANDRU | Sale | 3,212 | — |
| 2026-06-02 | KESWANI, SANJAY CHANDRU | Buy | 3,212 | — |
| 2026-06-02 | KESWANI, SANJAY CHANDRU | Sale | 1,733 | $154.84 |
Peer comparison
Smart narrative
Neurocrine Biosciences Inc trades at $150.59. representing a P/E of 24.58x trailing earnings. Our Smart Value Score of 81/100 indicates the stock is excellent. The company scores 3/9 on the Piotroski F-Score. With an Altman Z-Score of 3.08, it sits in the safe zone. TTM revenue stands at $3.10B. with profit margins at 21.50%.
Frequently asked questions
What is Neurocrine Biosciences Inc's stock price?
Neurocrine Biosciences Inc (NBIX) trades at $150.59, on a P/E of 24.6x and a P/S of 5.2x. Those multiples show what the market is paying for each dollar of earnings and sales, which is the real starting point for judging whether the price is reasonable.
Is Neurocrine Biosciences Inc overvalued?
Neurocrine Biosciences Inc carries a Smart Value Score of 81/100 (Grade A), which we rate Strong Buy. That score blends growth, quality, and valuation into one read.
What is the price target of Neurocrine Biosciences Inc (NBIX)?
The 12-month analyst consensus target is $190.99, about 26.8% above the current $150.59. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.
What is the future stock price of NBIX by 2030?
Our research-backed model puts the 2030 base case at $247.77, built from revenue projections, a growth-adjusted P/S multiple, net debt, and share dilution. It is a scenario rather than a prediction, and the bull and bear cases around it matter more than the single number when you are sizing a position.
What is Neurocrine Biosciences Inc's revenue?
Neurocrine Biosciences Inc's trailing twelve-month revenue is $3.10B, and our model projects it reaching about $7.05B by 2030. Revenue scale anchors the valuation multiples and shows whether growth is reaching the top line, so it is best read alongside margin and growth trends to see if that revenue is getting more profitable over time.
Altman Z-Score?
Neurocrine Biosciences Inc's Altman Z-Score is 3.08, which places it in the safe zone. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.
Company info
SectorHEALTHCARE
IndustryDRUG MANUFACTURERS - SPECIALTY & GENERIC
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio5.18x
ROE19.62%
Beta0.40
50D MA$145.45
200D MA$140.91
Shares out0.10B
Float0.10B
Short ratio—
Avg volume1.2M
Performance
1 week+0.00%
1 month+3.45%
3 months+26.21%
YTD+15.55%
1 year—
3 years—
5 years—